Shelley Morris, MSc,  —

Recent Posts

• FDA questions NurOwn’s efficacy, quality ahead of today’s hearing
• ALS affects my hand strength, but it’s no match for my determination
• Canadian initiative to advance AI tech to better diagnose ALS
• Dosing of healthy adults begins in Phase 1 study of oral CVN293
• Early 2024 eyed for approval decision in EU on masitinib for ALS